The stock of Actinium Pharmaceuticals Inc (ATNM) has gone down by -1.65% for the week, with a -19.21% drop in the past month and a 25.19% rise in the past quarter. The volatility ratio for the week is 7.28%, and the volatility levels for the past 30 days are 7.52% for ATNM. The simple moving average for the past 20 days is -19.89% for ATNM’s stock, with a 5.19% simple moving average for the past 200 days.
Is It Worth Investing in Actinium Pharmaceuticals Inc (AMEX: ATNM) Right Now?
The 36-month beta value for ATNM is at 0.11. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATNM is 28.26M, and currently, shorts hold a 7.00% of that float. The average trading volume for ATNM on April 26, 2024 was 361.16K shares.
ATNM) stock’s latest price update
The stock price of Actinium Pharmaceuticals Inc (AMEX: ATNM) has dropped by -7.08 compared to previous close of 7.06. Despite this, the company has seen a fall of -1.65% in its stock price over the last five trading days. InvestorPlace reported 2024-04-15 that The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.
Analysts’ Opinion of ATNM
Many brokerage firms have already submitted their reports for ATNM stocks, with HSBC Securities repeating the rating for ATNM by listing it as a “Buy.” The predicted price for ATNM in the upcoming period, according to HSBC Securities is $11.60 based on the research report published on September 06, 2023 of the previous year 2023.
Cantor Fitzgerald gave a rating of “Overweight” to ATNM, setting the target price at $20 in the report published on September 08th of the previous year.
ATNM Trading at -15.13% from the 50-Day Moving Average
After a stumble in the market that brought ATNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.47% of loss for the given period.
Volatility was left at 7.52%, however, over the last 30 days, the volatility rate increased by 7.28%, as shares sank -17.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.62% upper at present.
During the last 5 trading sessions, ATNM fell by -1.65%, which changed the moving average for the period of 200-days by -7.87% in comparison to the 20-day moving average, which settled at $8.12. In addition, Actinium Pharmaceuticals Inc saw 29.13% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ATNM
Current profitability levels for the company are sitting at:
- -640.99 for the present operating margin
- -8.75 for the gross margin
The net margin for Actinium Pharmaceuticals Inc stands at -595.94. The total capital return value is set at -0.71. Equity return is now at value -94.92, with -49.91 for asset returns.
Based on Actinium Pharmaceuticals Inc (ATNM), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -22.4. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is 94.92.
Currently, EBITDA for the company is -51.13 million with net debt to EBITDA at 1.46. When we switch over and look at the enterprise to sales, we see a ratio of 1460.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.21.
Conclusion
In conclusion, Actinium Pharmaceuticals Inc (ATNM) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
